<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231224060516N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-23</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of traditional preparation rectal suppository in treatment of hemorrhoids</public_title>
      <acronym></acronym>
      <scientific_title>Effect of a traditional preparation rectal suppository from Commiphora mukul (Hook. Ex Stocks) Engl. And Allium porrum L. on hemorrhoids in comparison with conventional anti-hemorrhoid suppository: A double-blind controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74727</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients are divided into two groups of 40 people randomly by simple block randomization method. 
All subjects are made aware of the content of
the study and written informed consent was obtained
from each patient. 
Coding and sealing of both suppositories by a non-researcher of the study is done by simple block randomization method and using Random Number Generation software. 
During that time the doctor, researcher and patients are not aware of the block numbers.
Common anti-hemorrhoid suppositories are removed from the relevant company's packaging and placed in specially designed boxes for clinical trials, and the labels are removed.
The Colo-Rectal Evaluation of Clinical Therapeutics Scale questionnaire (CORECTS) questionnaire completed by individuals.
The Interventional group is taking a Traditional Rectal suppository and the control group Anti-hemorrhoid suppository. Both groups of people receive the Drugs in the form of sealed envelopes with a allocation concealment method, and it should be noted that the color and packaging of the both groups drugs are completely similar. The medication in all two groups is taking a rectal suppository for two weeks, twice a day. After the end of the consumption period, the patient's symptoms are evaluated by the questionnaire.
The data are collected after 14 days, and then the codes of the drug packages and related questionnaires are opened, Blinding description: The doctor and the patient are blinded in the study. The researcher provides the traditional rectal suppository and conventional anti-hemorrhoid suppository to the patient in sealed envelopes  with a allocation concealment method, and the color and packaging of the both groups are completely similar.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hemorrhoid.</hc_freetext>
      <i_freetext>Intervention 1: The intervention group: 28 rectal suppositories containing Commiphora mukul (Hook. Ex Stocks) Engl. and Allium porrum L. made by the researcher, BID for two weeks. Intervention 2: The control group: 28 conventional anti hemorrhoid suppositories containing hydrocortisone acetate, lidocaine, aluminum sub acetate and zinc oxide, BID for two weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only a part of data like primary outcome can be shared.

When:
The access period starts 1 year after the publication time of results

To whom:
This data will be available only to researchers working in academic and scientific institutions.

Conditions:
The data will be made available to researchers for further studies or more advanced analysis.

Where to obtain:
Researchers can send an email regarding the request for the data of our study to Dr. Abdolali Mohagheghzadeh. Email: mohaghegh@sums.ac.ir

How to obtain:
The researchers can request for this study's data through an e-mail one year after the publication data of this study in one of the pee-reviewed journals.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Motahare Nayebzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Karafarin Street, Rokn abad Town</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۴۶۸۶۴۶۸۵</zip>
        <telephone>+98 71 3235 5677</telephone>
        <email>motaharenayeb@sums.ac.ir</email>
        <affiliation>Faculty of pharmacy</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abdolali Mohagheghzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Karafarin Street, Rokn abad Town</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۴۶۸۶۴۶۸۵</zip>
        <telephone>+98 71 3242 4128</telephone>
        <email>mohaghegh@sums.ac.ir</email>
        <affiliation>Department of Traditional Pharmacy, School of Pharmacy</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Suffering from hemorrhoids based on the diagnosis of a general surgeon that does not require emergency surgery
The patient must sign a consent form and cooperate during the study
Has not been treated for hemorrhoids in the past month</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Fourth-degree hemorrhoids
Pregnancy
Breastfeeding
Diabetes
Portal hypertension
Various known coagulopathy
Liver and kidney failure
Inflammatory bowel diseases
Perianal fissure
Anal fistula
Taking medication for hemorrhoids in the last 1 month
History Hemorrhoid surgery in the last 6 months
Thrombosed external hemorrhoid
Strangulated internal hemorrhoid
Anal abscess
History of perianal surgery
Mucosal prolapse
Cancer and other malignancies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K64</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hemorrhoids and perianal venous thrombosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The intervention group: 28 rectal suppositories containing Commiphora mukul (Hook. Ex Stocks) Engl. and Allium porrum L. made by the researcher, BID for two weeks</i_keyword>
      <i_keyword>The control group: 28 conventional anti hemorrhoid suppositories containing hydrocortisone acetate, lidocaine, aluminum sub acetate and zinc oxide, BID for two weeks</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before intervention, 2 weeks after initiation of intervention. Method of measurement: Colo-Rectal Evaluation of Clinical Therapeutics Scale questionnaire (CORECTS).</prim_outcome>
      <prim_outcome>Itching. Timepoint: Before intervention, 2 weeks after initiation of intervention. Method of measurement: Colo-Rectal Evaluation of Clinical Therapeutics Scale questionnaire (CORECTS).</prim_outcome>
      <prim_outcome>Swelling. Timepoint: Before intervention, 2 weeks after initiation of intervention. Method of measurement: Colo-Rectal Evaluation of Clinical Therapeutics Scale questionnaire (CORECTS).</prim_outcome>
      <prim_outcome>Bleeding. Timepoint: Before intervention, 2 weeks after initiation of intervention. Method of measurement: Colo-Rectal Evaluation of Clinical Therapeutics Scale questionnaire (CORECTS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-08</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Central Building of Medical Sciences, Zand Street. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
